Nuformix plc (NFX) - Total Assets
Based on the latest financial reports, Nuformix plc (NFX) holds total assets worth GBX1.86 Million GBX (≈ $226.75 USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nuformix plc - Total Assets Trend (2014–2025)
This chart illustrates how Nuformix plc's total assets have evolved over time, based on quarterly financial data. Also see Nuformix plc (NFX) market capitalisation for the company's overall valuation and market capitalisation.
Nuformix plc - Asset Composition Analysis
Current Asset Composition (September 2025)
Nuformix plc's total assets of GBX1.86 Million consist of 13.4% current assets and 86.6% non-current assets. Review NFX liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 9.6% |
| Accounts Receivable | GBX16.05K | 1.6% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX882.78K | 86.6% |
Asset Composition Trend (2014–2025)
This chart illustrates how Nuformix plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NFX stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nuformix plc's current assets represent 13.4% of total assets in 2025, a decrease from 88.4% in 2014.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, down from 19.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 86.0% of total assets, an increase from 10.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 86.6% of total assets.
Nuformix plc Competitors by Total Assets
Key competitors of Nuformix plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Nuformix plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.32 | 0.61 | 5.62 |
| Quick Ratio | 4.32 | 0.61 | 5.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX753.65K | GBX-89.17K | GBX1.50 Million |
Nuformix plc - Advanced Valuation Insights
This section examines the relationship between Nuformix plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | GBX1.02 Million |
| Market Capitalization | $49.22K USD |
Valuation Analysis
Below Book Valuation: The market values Nuformix plc's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nuformix plc's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nuformix plc (2014–2025)
The table below shows the annual total assets of Nuformix plc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | GBX1.02 Million ≈ $123.97 |
+4.98% |
| 2024-09-30 | GBX970.54K ≈ $118.09 |
-78.03% |
| 2023-09-30 | GBX4.42 Million ≈ $537.55 |
-1.86% |
| 2023-03-31 | GBX4.50 Million ≈ $547.73 |
-9.53% |
| 2022-03-31 | GBX4.98 Million ≈ $605.41 |
-17.22% |
| 2021-03-31 | GBX6.01 Million ≈ $731.35 |
+17.25% |
| 2020-03-31 | GBX5.13 Million ≈ $623.74 |
+10.61% |
| 2019-03-31 | GBX4.63 Million ≈ $563.93 |
-7.80% |
| 2018-03-31 | GBX5.03 Million ≈ $611.66 |
+25519.91% |
| 2017-03-31 | GBX19.62K ≈ $2.39 |
-96.40% |
| 2016-03-31 | GBX544.79K ≈ $66.29 |
-24.81% |
| 2015-12-31 | GBX724.59K ≈ $88.16 |
+157.86% |
| 2015-07-31 | GBX281.00K ≈ $34.19 |
-47.40% |
| 2014-07-31 | GBX534.27K ≈ $65.00 |
-- |
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more